260 related articles for article (PubMed ID: 35008687)
21. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors.
Ahmed WS; Geethakumari AM; Biswas KH
Biomed Pharmacother; 2021 Feb; 134():111128. PubMed ID: 33348311
[TBL] [Abstract][Full Text] [Related]
22. Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle.
Murthy KS
Biochem J; 2001 Nov; 360(Pt 1):199-208. PubMed ID: 11696008
[TBL] [Abstract][Full Text] [Related]
23. A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity.
Whitt JD; Li N; Tinsley HN; Chen X; Zhang W; Li Y; Gary BD; Keeton AB; Xi Y; Abadi AH; Grizzle WE; Piazza GA
Cancer Prev Res (Phila); 2012 Jun; 5(6):822-33. PubMed ID: 22556201
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
[TBL] [Abstract][Full Text] [Related]
25. Cyclic GMP in Liver Cirrhosis-Role in Pathophysiology of Portal Hypertension and Therapeutic Implications.
Kreisel W; Lazaro A; Trebicka J; Grosse Perdekamp M; Schmitt-Graeff A; Deibert P
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638713
[TBL] [Abstract][Full Text] [Related]
26. The NO-cGMP-PKG pathway in skeletal remodeling.
Kim SM; Yuen T; Iqbal J; Rubin MR; Zaidi M
Ann N Y Acad Sci; 2021 Mar; 1487(1):21-30. PubMed ID: 32860248
[TBL] [Abstract][Full Text] [Related]
27. In vivo reconstitution of the negative feedback in nitric oxide/cGMP signaling: role of phosphodiesterase type 5 phosphorylation.
Mullershausen F; Russwurm M; Koesling D; Friebe A
Mol Biol Cell; 2004 Sep; 15(9):4023-30. PubMed ID: 15240816
[TBL] [Abstract][Full Text] [Related]
28. Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling.
Mullershausen F; Friebe A; Feil R; Thompson WJ; Hofmann F; Koesling D
J Cell Biol; 2003 Mar; 160(5):719-27. PubMed ID: 12604588
[TBL] [Abstract][Full Text] [Related]
29. Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation.
Mujoo K; Sharin VG; Martin E; Choi BK; Sloan C; Nikonoff LE; Kots AY; Murad F
Nitric Oxide; 2010 Jan; 22(1):43-50. PubMed ID: 19948239
[TBL] [Abstract][Full Text] [Related]
30. Differential expression of multidrug resistance protein 5 and phosphodiesterase 5 and regulation of cGMP levels in phasic and tonic smooth muscle.
Al-Shboul O; Mahavadi S; Sriwai W; Grider JR; Murthy KS
Am J Physiol Gastrointest Liver Physiol; 2013 Aug; 305(4):G314-24. PubMed ID: 23764893
[TBL] [Abstract][Full Text] [Related]
31. Targeting the paracrine hormone-dependent guanylate cyclase/cGMP/phosphodiesterases signaling pathway for colorectal cancer prevention.
Yarla NS; Gali H; Pathuri G; Smriti S; Farooqui M; Panneerselvam J; Kumar G; Madka V; Rao CV
Semin Cancer Biol; 2019 Jun; 56():168-174. PubMed ID: 30189250
[TBL] [Abstract][Full Text] [Related]
32. Icariin stimulates the osteogenic differentiation of rat bone marrow stromal cells via activating the PI3K-AKT-eNOS-NO-cGMP-PKG.
Zhai YK; Guo XY; Ge BF; Zhen P; Ma XN; Zhou J; Ma HP; Xian CJ; Chen KM
Bone; 2014 Sep; 66():189-98. PubMed ID: 24956021
[TBL] [Abstract][Full Text] [Related]
33. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
de Vente J; Markerink-van Ittersum M; Vles JS
J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
[TBL] [Abstract][Full Text] [Related]
34. Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change.
Jensen BO; Kleppe R; Kopperud R; Nygaard G; Døskeland SO; Holmsen H; Selheim F
Platelets; 2011; 22(1):8-19. PubMed ID: 20958117
[TBL] [Abstract][Full Text] [Related]
35. Preservation of nitric oxide-induced relaxation of porcine coronary artery: roles of the dimers of soluble guanylyl cyclase, phosphodiesterase type 5, and cGMP-dependent protein kinase.
Liu J; Chen Z; Ye L; Liu H; Dou D; Liu L; Yu X; Gao Y
Pflugers Arch; 2014 Oct; 466(10):1999-2008. PubMed ID: 24413911
[TBL] [Abstract][Full Text] [Related]
36. PDE5 modulates oocyte spontaneous maturation via cGMP-cAMP but not cGMP-PKG signaling.
Wang S; Ning G; Chen X; Yang J; Ouyang H; Zhang H; Tai P; Mu X; Zhou B; Zhang M; Xia G
Front Biosci; 2008 May; 13():7087-95. PubMed ID: 18508718
[TBL] [Abstract][Full Text] [Related]
37. Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition.
Tinsley HN; Gary BD; Thaiparambil J; Li N; Lu W; Li Y; Maxuitenko YY; Keeton AB; Piazza GA
Cancer Prev Res (Phila); 2010 Oct; 3(10):1303-13. PubMed ID: 20876730
[TBL] [Abstract][Full Text] [Related]
38. Essential role of the cGMP/PKG signaling pathway in regulating the proliferation and survival of human renal carcinoma cells.
Ren Y; Zheng J; Yao X; Weng G; Wu L
Int J Mol Med; 2014 Nov; 34(5):1430-8. PubMed ID: 25244411
[TBL] [Abstract][Full Text] [Related]
39. Role of the nitric oxide-soluble guanylyl cyclase pathway in obstructive airway diseases.
Dupont LL; Glynos C; Bracke KR; Brouckaert P; Brusselle GG
Pulm Pharmacol Ther; 2014 Oct; 29(1):1-6. PubMed ID: 25043200
[TBL] [Abstract][Full Text] [Related]
40. Priming metabolism with the type 5 phosphodiesterase: the role of cGMP-hydrolyzing enzymes.
Campolo F; Pofi R; Venneri MA; Isidori AM
Curr Opin Pharmacol; 2021 Oct; 60():298-305. PubMed ID: 34507030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
